Department of Justice March 9, 2017 – Federal Register Recent Federal Regulation Documents

Sunshine Act Meeting
Document Number: 2017-04739
Type: Notice
Date: 2017-03-09
Agency: Foreign Claims Settlement Commission, Department of Justice
Schedules of Controlled Substances: Placement of Brivaracetam Into Schedule V
Document Number: 2017-04698
Type: Rule
Date: 2017-03-09
Agency: Drug Enforcement Administration, Department of Justice
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12, 2016. The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015.
Notice of Federal Advisory Committee Meeting
Document Number: 2017-04695
Type: Notice
Date: 2017-03-09
Agency: Department of Justice
The National Commission on Forensic Science will hold meeting thirteen at the time and location listed below.
Importer of Controlled Substances Application: Meda Pharmaceuticals, Inc.
Document Number: 2017-04648
Type: Notice
Date: 2017-03-09
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Application: Meridian Medical Technologies
Document Number: 2017-04647
Type: Notice
Date: 2017-03-09
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances Application: Myoderm
Document Number: 2017-04646
Type: Notice
Date: 2017-03-09
Agency: Drug Enforcement Administration, Department of Justice
Bulk Manufacturer of Controlled Substances Application: Mallinckrodt, LLC
Document Number: 2017-04645
Type: Notice
Date: 2017-03-09
Agency: Drug Enforcement Administration, Department of Justice